Smith Adam B, Ravikumar Thanjavur S, Kamin Marc, Jordan Donna, Xiang Jim, Rosenthal Norman
Department of Surgery, University of North Texas Health Science Center, 855 Montgomery St., Fort Worth, TX 76107, USA.
Am J Surg. 2004 Apr;187(4):521-7. doi: 10.1016/j.amjsurg.2003.12.038.
This multicenter, randomized, double-blind, active- and placebo-controlled trial evaluated tramadol plus acetaminophen (APAP) for orthopedic (n = 153) and abdominal (n = 152) postsurgical pain.
Patients with moderate pain or greater were randomized to an initial two tablets of 37.5 mg tramadol plus 325 mg APAP (n = 98), codeine 30 mg plus APAP 300 mg (n = 109), or placebo (n = 98); thereafter, they received 1 to 2 tablets every 4 to 6 hours as needed for pain for 6 days. Outcome measures were pain relief and pain intensity, total pain relief, sum of pain intensity differences, and sum of pain relief and pain intensity differences during 4 hours and the daily averages.
Tramadol plus APAP was superior to placebo for total pain relief, sum of pain intensity differences, and sum of pain relief and pain intensity differences (P < or =0.015); tramadol plus APAP and codeine plus APAP did not separate (P > or=0.281). For average daily pain relief, average daily pain intensity, and overall medication assessment, tramadol plus APAP was superior to placebo (P < or =0.038); codeine plus APAP did not separate from placebo (P > or =0.125). Discontinuation because of adverse events occurred in 8.2% of tramadol plus APAP, 10.1% of codeine plus APAP, and 3.0% of placebo patients. Except for constipation (4.1% tramadol plus APAP vs 10.1% codeine plus APAP) and vomiting (9.2% vs 14.7%, respectively), adverse events were similar for active treatments.
Tramadol plus APAP (mean dose 4.4 tablets) was effective and well tolerated for postsurgical pain and showed better tolerability than did codeine plus APAP.
这项多中心、随机、双盲、活性药物与安慰剂对照试验评估了曲马多加对乙酰氨基酚(APAP)用于骨科手术(n = 153)和腹部手术(n = 152)后疼痛的疗效。
中度或更严重疼痛的患者被随机分为初始服用两片37.5毫克曲马多加325毫克APAP(n = 98)、30毫克可待因加300毫克APAP(n = 109)或安慰剂(n = 98);此后,根据疼痛情况每4至6小时按需服用1至2片,持续6天。观察指标为疼痛缓解情况、疼痛强度、总疼痛缓解情况、疼痛强度差值总和以及4小时内和每日平均值的疼痛缓解与疼痛强度差值总和。
曲马多加APAP在总疼痛缓解、疼痛强度差值总和以及疼痛缓解与疼痛强度差值总和方面优于安慰剂(P≤0.015);曲马多加APAP与可待因加APAP无显著差异(P≥0.281)。对于平均每日疼痛缓解、平均每日疼痛强度和总体药物评估,曲马多加APAP优于安慰剂(P≤0.038);可待因加APAP与安慰剂无显著差异(P≥0.125)。因不良事件停药的患者比例在曲马多加APAP组为8.2%,可待因加APAP组为10.1%,安慰剂组为3.0%。除便秘(曲马多加APAP组为4.1%,可待因加APAP组为10.1%)和呕吐(分别为9.2%和14.7%)外,活性药物治疗组的不良事件相似。
曲马多加APAP(平均剂量4.4片)对术后疼痛有效且耐受性良好,并且比可待因加APAP耐受性更好。